BLS Pharmaceuticals Limited
BLS.AX
Get informed when a big investor buys or sells
+ FollowMarket Cap$233.69M
Close$
Share Statistics
| Market cap | $233.69 Million |
|---|---|
| Enterprise Value | $235.09 Million |
| Dividend Yield | $- (NaN%) |
| Earnings per Share | $- |
| Beta | 0.62 |
| Outstanding Shares | - |
Return
| Return on Equity | 55.54% |
|---|---|
| Return on Assets | 32.35% |
| Return on Invested Capital | 49.73% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 3.54 |
| Enterprise Value to EBIT | 19.43 |
| Enterprise Value to Net Income | 20 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.45 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About BLS Pharmaceuticals Limited
CEO: Sam Watson BLS Pharmaceuticals Ltd. engages in the research, development, market and distribution of health products. It operates through the following segments: Wholesale, Plant Based, and Direct Sales. The Wholesale segment covers operation in Un...